Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia

Completed

Conditions: Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer

Interventions: Other: No intervention

First Posted Date: 2015-06-03

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 22

Registration Number: NCT02461316

Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1

Completed

Conditions: Follicular Lymphoma

Interventions: Radiation: Chemotherapy
Drug: Rituximab

First Posted Date: 2015-06-03

Last Posted Date: 2015-09-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 99

Registration Number: NCT02461290

A Study of Atezolizumab in Advanced Solid Tumors

Phase 2

Completed

Conditions: Tumors

Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody

First Posted Date: 2015-06-01

Last Posted Date: 2021-06-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 474

Registration Number: NCT02458638

Locations: 🇮🇪
St Vincent'S Uni Hospital; Medical Oncology, Dublin, Ireland
🇳🇴
Oslo Universitetssykehus HF; Radiumhospitalet, Oslo, Norway
🇨🇭
Freiburger Spital; Onkologie, Fribourg, Switzerland

and more 45 locations

Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China

Completed

Conditions: Non-Small Cell Lung Cancer, Lung Cancer, Cancer

Interventions: Other: No intervention

First Posted Date: 2015-06-01

Last Posted Date: 2018-11-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1378

Registration Number: NCT02458651

Locations: 🇨🇳
Sichuan Provincial Cancer Hospital, Chengdu, China
🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China
🇨🇳
the First Hospital of Jilin University, Changchun, China

and more 8 locations

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

Phase 3

Completed

Conditions: Systemic Sclerosis

Interventions: Drug: Placebo
Drug: Tocilizumab

First Posted Date: 2015-05-25

Last Posted Date: 2020-03-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 212

Registration Number: NCT02453256

Locations: 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇫🇷
Hopital Claude Huriez; Internal Medicine, Lille, France
🇺🇸
Joint & Muscle Research Institute, Charlotte, North Carolina, United States

and more 80 locations

A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: DCDS0780A
Drug: Rituximab
Drug: Obinutuzumab

First Posted Date: 2015-05-25

Last Posted Date: 2019-08-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 66

Registration Number: NCT02453087

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸
New York University Cancer Cen, New York, New York, United States
🇺🇸
Medical Center of Aurora; Rocky Mountain Cancer Centers, Aurora, Colorado, United States

and more 4 locations

Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

Completed

Conditions: HCV

First Posted Date: 2015-05-25

Last Posted Date: 2018-02-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 8

Registration Number: NCT02452814

Locations: 🇺🇸
Methodist Transplant Physicians, Dallas, Texas, United States
🇵🇷
Fundacion de Investigacion de Diego, San Juan, Puerto Rico
🇺🇸
Research Specialists of Texas, Houston, Texas, United States

Non-drug Study to Evaluate the Suitability of Neurocognitive Tests and Functioning Scales for the Measurement of Cognitive and Functioning Changes in Children With Down Syndrome

Completed

Conditions: Down Syndrome

Interventions: Other: No Intervention

First Posted Date: 2015-05-22

Last Posted Date: 2017-10-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT02451657

Locations: 🇪🇸
Hospital Infantil Universitario Niño Jesus; Pediatria Social, Madrid, Spain
🇺🇸
University of Arizona, Tucson, Arizona, United States
🇪🇸
IMIM, Human Pharmacology and Clinical Neurosciences,, Barcelona, Spain

and more 7 locations

A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

Phase 3

Terminated

Conditions: Carcinoma, Transitional Cell

Interventions: Drug: Atezolizumab

First Posted Date: 2015-05-21

Last Posted Date: 2023-06-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 809

Registration Number: NCT02450331

Locations: 🇺🇸
Chesapeake Urology Research Associates, Towson, Maryland, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Fairview Hospital; Cleveland Clinic Cancer Center, Cleveland, Ohio, United States

and more 183 locations

Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Pertuzumab
Drug: Trastuzumab

First Posted Date: 2015-05-15

Last Posted Date: 2019-10-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 52

Registration Number: NCT02445586

Locations: 🇮🇳
Rajiv Gandhi Cancer Institute & Research Center, New Delhi, Delhi, India
🇮🇳
Jehangir Clinical Development Centre Pvt. Ltd; Cancer Research Room, Pune, Maharashtra, India
🇮🇳
Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy